CytomX Therapeutics to Present at Cowen and Company 40th Annual Health Care Conference
2020年2月25日 - 10:00PM
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage
oncology-focused biopharmaceutical company pioneering a novel class
of investigational antibody therapeutics based on its Probody®
therapeutic technology platform, today announced that Sean
McCarthy, D.Phil., president, chief executive officer and chairman,
will participate at Cowen and Company’s 40th Annual Health Care
Conference in Boston, Massachusetts.
|
Date: |
|
Tuesday, March
3, 2020 |
|
Time: |
|
10:00 a.m. E.T / 7:00 a.m. P.T. |
|
Location: |
|
Boston, Massachusetts |
A live audio of this webcast will be available through the
“Investors & News” section of CytomX's website. An archived
replay will be available for 60 days following the event.
About CytomX Therapeutics
CytomX is a clinical-stage, oncology-focused biopharmaceutical
company with a vision of transforming lives with safer, more
effective therapies. We are developing a novel class of
investigational antibody therapeutics, based on our Probody®
technology platform, for the treatment of cancer. As leaders in the
field, our innovative technology is designed to turn previously
undruggable targets into druggable targets and to enable more
effective combination therapies. CytomX and its partners, comprised
of leading biotechnology and pharmaceutical companies, have
developed a robust pipeline of potential best-in-class
immunotherapies against clinically validated targets and potential
first-in-class therapeutics against novel, difficult to drug
targets. Five novel drug-candidates utilizing our Probody
technology are in the clinic, with three in Phase 2 studies and two
in Phase 1 studies. These clinical programs include cancer
immunotherapies against validated targets such as a PD-L1-targeting
Probody therapeutic wholly owned by CytomX (CX-072) and a
CTLA-4-targeting Probody therapeutic partnered with Bristol-Myers
Squibb (BMS-986249). The CytomX clinical stage pipeline also
includes first-in-class Probody drug conjugates against previously
undruggable targets, including a CD166-targeting Probody drug
conjugate wholly owned by CytomX (CX-2009) and a CD71-targeting
Probody drug conjugate partnered with AbbVie (CX-2029). CD166 and
CD71 are among cancer targets that are considered to be
inaccessible to conventional antibody drug conjugates due to their
presence on many healthy tissues. In addition to its wholly owned
programs, CytomX has strategic collaborations with AbbVie, Amgen
and BMS. For additional information about CytomX Therapeutics,
visit www.cytomx.com and follow us on LinkedIn and Twitter.
Probody® is a registered trademark of CytomX Therapeutics
Inc.
Contact:
Investors and Media:
Christopher KeenanVP, Investor Relations and Corporate
Communicationsckeenan@cytomx.com650-383-0823
CytomX Therapeutics (NASDAQ:CTMX)
過去 株価チャート
から 6 2024 まで 7 2024
CytomX Therapeutics (NASDAQ:CTMX)
過去 株価チャート
から 7 2023 まで 7 2024